微生物与生化药学——药物化学方向
薛司徒
来源：
作者：
时间：2021-07-07
浏览次数：
薛司徒 有机化学室 研究员 博士生导师
教育背景及工作经历：
2023至今 中国医学科学院医药生物技术研究所 研究员
2016-2023 中国医学科学院医药生物技术研究所 副研究员
2013-2016 中国医学科学院医药生物技术研究所 助理研究员
2008-2013 北京协和医学院医药生物技术研究所 医学博士
2004-2008 北京大学药学院 理学学士
主要研究方向：抗肿瘤药物研究 药物化学生物学研究
专业研究领域：通过化学生物学与现代生物信息技术，开展高发难治恶性肿瘤潜在药物靶标及药物发现研究。近五年，主持国家自然科学基金面上项目3项，中国健康长寿创新大赛支持项目1项，北京协和医学院“药学双一流学科建设”项目1项。以第一或通讯作者身份在Autophagy, Nat. Commum., J. Med. Chem., Eur. J. Med. Chem., Acta. Pha.r Sinica. B等国内外学术期刊发表论文，获得中国、美国、欧洲、日本等发明专利。
代表性论文：
1. 2020 / The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target. / Xue ST1, Li K1, Gao Y, Zhao LY, Gao Y, Yi H, Jiang JD*, Li ZR*. / Autophagy / IF: 16.0.
2. 2023 / SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity. / Wang F1, Gao Y1, Xue ST1, Zhao LY, Jiang HM, Zhang TT, Li YX, Zhao CX, Wu F, Siqin T, Liu Y, Wu J, Yan YC, Yuan J*, Jiang JD*, Li K*. / Nat. Commun. / IF: 16.6.
3. 2022 / Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment. / Xie ZS, Han XY, Zhou ZY, Li SY, Zhu JY, Zhang L*, Xue ST*. / Biomed. Pharmacother. / IF: 7.5.
4. 2023 / Efficacy, Mechanism, and Structure-Activity Relationship of 6-Methoxy Benzofuran Derivatives as a Useful Tool for Senile Osteoporosis. / Zhou ZY, Sun LQ, Han XY, Wang YJ, Xie ZS, Xue ST*, Li ZR*. / J. Med. Chem. / IF: 7.3.
5. 2022 / Synthesis and antineoplastic activity of ethylene glycol phenyl aminoethyl ether derivatives as FOXM1 inhibitors. / Gao Y1, Geng J1, Xie ZS, Zhou ZY, Yang HX, Yi H, Han XY, Xue ST*, Li ZR*. / Eur. J. Med. Chem. / IF: 6.7.
6. 2020 / Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties. / Xue ST1, Zhang L1, Xie ZS, Jin J, Guo HF, Yi H, Liu ZY*, Li ZR*. / Eur. J. Med. Chem. / IF: 6.5
7. 2016 / Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents. / Wu LT1, Jiang Z1, Shen JJ, Yi H, Zhan YC, Sha MQ, Wang Z, Xue ST*, Li ZR*. Eur. J. Med. Chem. / IF: 4.5.
8. 2022 / Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer. / Zhang Z1, Xue ST1, Gao Y, Li Y, Zhou Z, Wang J, Li Z*, Liu Z*. / Cell Death Discov. / IF: 7.0.
9. 2022 / Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer. / Zhou ZY1, Han XY1, Sun LQ, Li SY, Xue ST*, Li ZR*. / Front Chem. / IF: 5.5.
10. 2023 / Advances in inhibitors of potential tumor target FOXM1. / Han XY, Zhou ZY, Li SY, Xue ST*. / Future Med. Chem. / IF: 4.2.
联系电话：010-63151107
电子邮箱：xuesitu@imb.pumc.edu.cn
